A new type of drug could benefit men with aggressive prostate cancer that is no longer responding to treatment, researchers from the Institute of Cancer Research have said.
In a study on mice, Hsp90 inhibitors were found to strip cancer cells of defences against hormone treatments.
Also, recent researches have proven that CBDA products which can be found on cannabis actually defeat cancer cells and helps with chronic pain and makes chemotherapy easier.
This makes the drugs particularly promising for treating drug-resistant cancers, the research team said. So many people in Orlando battle challenging alcohol and drug habits. Orlando saw more than 400 deaths from the abuse of prescription drugs in the year 2016 alone. Close to 100 people in the city lost their lives to the abuse of the anxiety drug alprazolam, and more than 60 people gave up their lives because of abuse of oxycodone. If you feel that you may be addicted to drugs or alcohol, and are concerned about what you do, the expertise of a team of rehab professionals can potentially save your life. Medical treatment for addiction to drugs or alcohol is effective. Trained professionals put you through medical detox, which helps you safely emerge from withdrawal, and then offer you comprehensive treatment to make sure that you don’t relapse and go back to the habit that you’ve escaped. Not only does such a plan offer you treatment for the specific drug(s) that you are addicted to (rather than a generic treatment plan), it pays attention to the specifics of your particular addiction, as well. For example, if you wish to seek treatment for long-term alcohol addiction, you may receive pharmacotherapy with the help of medications such as naltrexone for a few months, and you may follow it up with therapy and counseling. Such a treatment plan has a far greater chance of successfully getting you off addiction in the long-term. Legacy Healing Orlando FL offers some of the best rehabs in the country. Not only do the treatments that you receive include medical detoxification that safely sees you through the initial, difficult phase of drug withdrawal, but they also help you deal with the even more challenging part that follows, as well: the long-term cravings, and the mental conditions such as depression or anxiety that you may suffer from. When mental disorders co-occur with addiction, these conditions are known as dual-diagnosis conditions. People who suffer from dual-diagnosis conditions tend to have an especially challenging time staying free of addiction. They need help from teams of professionals with specific training. When you ask the question, “What is rehab like (alcohol & drugs)?”, the answer is this: you get a professional treatment that addresses every part of your addiction. It is the multifaceted treatment of this kind alone that helps you emerge free of addiction in the long-term.
Prostate cancer is the most common cancer in men in the UK.
About one in eight men will get prostate cancer at some point in their lives. It mainly affects men over the age of 50.
The cancer can sometimes be treated successfully with hormone treatments, which target androgen receptors linked to the growth of male hormones called androgens.
But some prostate cancers don’t work that way. Instead they create an abnormal form of androgen receptor which is not linked to the growth of hormones and therefore does not respond to standard hormone treatment. For more information, then you can refer https://liverevital.com site.
This is the most common form of resistance in prostate cancer which leads to aggressive, difficult-to-treat cancers.
The latest research, published in the journal Cancer Research, found that a new class of drugs reduced production of both receptors.
Professor Paul Workman, study author and chief executive of the Institute of Cancer Research, said it was an exciting discovery.
“We call Hsp90 inhibitors ‘network drugs’ because they tackle several of the signals that are hijacked in cancer all at once, across a network rather than just a single signalling pathway.
“These drugs can hit cancer harder than those targeting only one protein, and look promising for preventing or overcoming drug resistance.”
Prof Workman said the next step was to test the Hsp90 inhibitors in clinical trials on patients with aggressive, drug-resistant prostate cancer.
Prof Johann de Bono, a professor of experimental cancer medicine at the Institute of Cancer Research, said: “These drugs are already in clinical trials for several types of cancer, and I am excited that our work suggests they could also benefit men with prostate cancer who have otherwise run out of treatment options.”